Cancer Cell International (Mar 2024)

RBP7 functions as a tumor suppressor in HR + breast cancer by inhibiting the AKT/SREBP1 pathway and reducing fatty acid

  • Yue Yu,
  • Zhihua Xu,
  • Hao Zhou,
  • Ruyan Xu,
  • Jia Xu,
  • Wenjun Liu,
  • Yuxin Wu,
  • Yue Qiu,
  • Guangbo Zhang,
  • Xue Huang,
  • Yan Chen

DOI
https://doi.org/10.1186/s12935-024-03299-0
Journal volume & issue
Vol. 24, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Background Increasing evidence proves that RBP7 plays a significant role in breast cancer (BC). The present study was aimed to investigate the mechanism of RBP7. Methods Western Blotting and qRT-PCR were performed for evaluating the expression levels. CCK8, colony forming, xenograft mouse model, wound healing and transwell assays were conducted to examine cell ability of proliferation, invasion and migration. Nile red staining and Oil red O staining were used for testing the lipid. Results RBP7 was related to overall survival (OS) in patients with HR + BC. RBP7 protein was significantly decreased in HR + BC tissues and cells. RBP7 suppressed HR + BC cell proliferation in vitro and in vivo, and inhibited migration and invasion. RBP7 reduced fatty acid in HR + BC cells by inhibiting the AKT/SREBP1 pathway. Conclusions RBP7 may function as a tumor suppressor in HR + BC by inhibiting the AKT/SREBP1 pathway and reducing fatty acid.

Keywords